Jax DiEugenio

Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Adjuvant nivolumab plus chemoradiotherapy improved disease-free survival in resected, locally advanced head and neck squamous cell carcinoma.

Roxana S. Dronca, MD, discusses the FDA approval of subcutaneous nivolumab across solid tumor indications.

The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.

The FDA has granted orphan drug designation for the treatment of patients with hepatocellular carcinoma.

Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.

Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.

Fueled by wanting to carry on his father’s legacy, Ralph R. Weichselbaum, MD, created his own mark on radiation therapy in oncologic care.

Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.

Roy S. Herbst, MD, explores evolving chemoimmunotherapy strategies for early-stage NSCLC that does not harbor actionable mutations.

R. Lor Randall, MD, FACS, discusses advancements in preclinical research identifying therapeutic vulnerabilities in soft tissue sarcomas.

DETECT V trial data suggest dual HER2-targeted and endocrine therapy might be an effective option in HER2+/HR+ breast cancer.

Monica H. Vetter, MD, discusses the integration of immunotherapy into chemotherapy regimens for frontline advanced endometrial cancer.

Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer.

Disitamab vedotin showed early activity in HER2-expressing metastatic breast cancer with abnormal PAM pathway activation.

ALLO-316, a CD70-directed CAR T-cell therapy, demonstrated preliminary efficacy and safety in CD70-positive ccRCC.

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

Tanios S. Bekaii-Saab, MD, discusses the role of liquid biopsies and ctDNA in gastrointestinal cancers.

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.

Brandon G. Smaglo, MD, FACP, discusses ongoing research with novel RAS inhibitors in pancreatic cancer.

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.

A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.

IBI354 showed favorable safety and efficacy in patients with advanced HER2-positive and HER2-low breast cancer.

Kathleen N. Moore, MD, MS, discusses the evolving treatment landscape of platinum-resistant ovarian cancer.

Trevor Leong, MBBS, MD, FRANZCR, discusses findings from the TOPGEAR trial assessing perioperative chemoradiotherapy in gastric/GEJ cancer.

Neoadjuvant SHR-A1811 plus pyrotinib generated response and had a manageable safety profile in HER2+ breast cancer.

Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.

Bradley C. Carthon, MD, PhD, discusses recent data and the evolving treatment landscape in prostate cancer.

The first-in-class CDK8/19 inhibitor RVU120 demonstrated early signs of clinical activity in patients with relapsed/refractory metastatic or advanced solid tumors.

David C. Fisher, MD, discusses the evolving therapeutic landscape in follicular lymphoma.